ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Varmus To Cut Five Percent From Cancer Centers As NCI Adjusts To “Financial disaster”

May 6, 2011

AACR Cancels $7 Million Annual Meeting, Citing Fear of SARS in Toronto

April 4, 2003

NSABP Executive Committee Joins Fisher In Suit Against Pitt

August 5, 1994

NCI Conducting Four Epidemiology Studies On Radon

July 1, 1988

In Brief: Chance for Rauscher Pay Increase Bill Seems Diminishing, But Schmidt Remains Confident

April 30, 1976

Professional societies: ACCC honors Clinton For Cancer Drug Initiatives, Insurance Bill

September 27, 1996